Atreca, Inc. announced a collaboration with the Bill & Melinda Gates Foundation to accelerate the discovery and development of novel vaccines and therapeutics for human infectious diseases. The US$6 million BMGF investment “…provides Atreca an opportunity to apply its Immune Repertoire Capture technology to meet key challenges in global health.” This technology “leverages next-generation sequencing to identify rapidly and comprehensively the set of functional antibodies produced in patients during an immune response. These antibodies both have utility themselves and can be employed to identify the targets of an immune response.  Applied to human disease, Immune Repertoire Capture is an engine for the discovery and development of antibody-based therapeutics, vaccines, diagnostics, and research reagents.  Atreca recently licensed exclusive rights to the technology for all fields of use from Stanford University.” Atreca is a privately held biopharmaceutical founded in 2010 with headquarters in San Carlos, California.

http://www.atreca.com/press/september-25-2012/